The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species

British Journal of Pharmacology

Volumn 138, Issue 3, 2003, Pages 501-511

  Phillips, Darren C ^a   Woollard, Kevin J ^a   Griffiths, Helen R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Adhesion; Apoptosis; Glutathione; Growth arrest; Immunosuppression; Inflammation; Methotrexate; Reactive oxygen species; Rheumatoid arthritis

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; LIPOPOLYSACCHARIDE; METHOTREXATE; PEROXIDE; REACTIVE OXYGEN METABOLITE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL GROWTH; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOSTASIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TIME; UMBILICAL VEIN;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, SURFACE; APOPTOSIS; CELL ADHESION; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; JURKAT CELLS; METHOTREXATE; MONOCYTES; PEROXIDES; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TIME FACTORS; U937 CELLS; UMBILICAL VEINS;

EID: 0037331142     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705054     Document Type: Article

References (62)

1. ALARCÓN, A. (2000). Methotrexate in rheumatoid arthritis. A clinician's perspective. Immunopharmacology, 47, 259-271.
2. ALLISON, A. (2000). Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 47, 63-83.
3. ALLDRED, A. (2001). Etanercept in rheumatoid arthritis. Expert Opin. Pharmacother., 2, 1137-1148.
4. ANDERSON, M. (1985). Determination of glutathione and glutathione disulfide in biological samples. In Methods in Enzymology. ed. Meister, A. 113, pp. 548-555. New York: Academic Press.
5. ANDERSSON, S., JOHANSSON, L.H., LEXMÜLLER, K. & EKSTRÖM, G. (2000). Anti-rheumatic effect of methotrexate: is it really mediated by adenosine? Eu. J. Pharm. Sci., 9, 333-343.
6. BABIAK, R., CAMPELLO, A., CARNIERI, E. & OLIVEIRA, M. (1998). Methotrexate; pentose cycle and oxidative stress. Cell Biochem. Funct., 16, 283-293.
7. BAGGOTT, J., MORGAN, S., HA, T., ALARCÓN, G., KOOPMAN, W. & KRUMDIECK, C. (1993). Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin. Exp. Rheumatol., 11, S101-S105.
8. BANNWARTH, B., LABAT, L. MORIDE, Y. & SCHAEVERBEKE, T. (1994). Methotrexate in rheumatoid arthritis: an update. Drugs, 47, 25-50.
9. BASS, D., PARCE, J., DECHATELET, L., SZEJDA, P., SEEDS, M. & THOMAS, M. (1983). Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol., 130, 910-917.
10. BONDESON, J. & SUNDLER, R. (1995). Auranofin inhibits the induction of interleukin 1 and tumour necrosis factor alpha mRNA in macrophages. Biochem. Pharmacol., 52, 35-42.
11. BUDZIK, G., COLLETTI, L. & FALTYNEK, C. (2000). Effects of methotrexate on nucleotide pools in normal T cells and the CEM T cell line. Life Sciences, 66, 2297-2307.
12. CHULUYAN, H. & ISSEKUTZ. (1993). VLA-4 can mediate CD11/CD18-independent transendothelial migration of human monocytes. J. Clin. Invest., 92, 2768-2777.
13. CIESIELSKI, C., MEI, J. & PICCININI, L. (1998a). Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts. Transpl. Immunol., 6, 122-123.
14. CIESIELSKI, C., PFLUG, J., MEI, J. & PICCININI, L. (1998b). Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Transpl. Immunol. 6, 111-121.
15. COOMBE, B., EDNO, L., LAFFORGUE, P., BOLOGNA, J., ACQUAVIVA, P., SANY, J. & BRESSOLLE, F. (1995). Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. J. Rheumatol., 34, 421-428.
16. COYLE, J. & PUTTFARKEN, P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science, 262, 689-695.
17. CRONSTEIN, B. (1994). Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol., 76, 5-13.
18. CRONSTEIN, B., ROSENSTEIN, E., KRAMER, S., WEISSMANN, G. & HIRSCHHORN, R. (1985). Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on neutrophils. J. Immunol., 135, 1366-1371.
19. CRONSTEIN, B., NAIME, D. & OSTAD, E. (1993). The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest, 92, 2675-2692.
20. CROSS, A. & JONES, O. (1991). Enzymatic mechanisms of superoxide production. Biochim. Biophys. Acta, 1057, 281-298.
21. DA SILVA, C., DE OLIVEIRA, C. & DE LIMA, M. (1996). Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol., 51, 1331-1340.
22. ELLIOTT, M., MAINI, R., FELDMANN, M., KALDEN, J., ANTONI, C., SMOLEN, J., LEEB, B., BREEDVELD, F., MACFARLANE, J., BIJL, H. & WOODY, J. (1994). Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet, 344, 1105-1110.
23. FAIRBANKS, L., RÜCKERMANN, K., QUI, Y., HAWRYLOWICZ, C., RICHARDS, D., SWAMINATHAN, R., KIRSCHBAUM, B. & SIMMONDS, H. (1999). Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis. Biochemical J., 342, 143-152.
24. FARBER, S., TOCH, R., SEARS, E. & PINKEL, D. (1956). Advances in chemotherapy of cancer in man. In Advances in Cancer Research. ed. Greebstein, J.-P. pp. 2-73. New York: Academic Press.
25. FELDMANN, M., BRENNAN, F. & MAINI, R. (1996). Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol., 14, 397-440.
26. GENESTIER, L., PAILLOT, R., FOURNAL, S., FERRARO, C., MIOSSEC, P. & REVILLARD, J.-P. (1998a). Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest., 102, 322-328.
27. GENESTIER, L., PRIGENT, A.-F., PAILLOT, R., QUEMENEUR, L., DURAND, I., BANCHEREAU, J., REVILLARD, J. & BONNEFOY-BÉRARD, N. (1998b). Caspase-dependent ceramide production in Fas- and HLA class I-mediated peripheral T cell apoptosis. J. Biol. Chem., 273, 5060-5066.
28. GRESSIER, B., LEBAEGUE, S., LUYCKX, M., DINE, T., CAZIN, M. & CAZIN, J. (1994). Pro-oxidant properties of methotrexate: evaluation and prevention by an anti-oxidant drug. Pharmazie, 49, 679-681.
29. HADDAD, J., SAADE, N. & SAFIEH-GARABEDIAN, B. (2002). Redox regulation of TNF-[alpha] biosynthesis: Augmentation by irreversible inhibition of [gamma]-glutamylcysteine synthetase and the involvement of I[kappa]B-[alpha]/NF-[kappa]B-independent pathway in alveolar epithelial cells. Cell Signal, 14, 211-218.
30. HALL, M., LAWRENCE, D., LANSIEDEL, J., WALSH, A., COMSTOCK, L. & KREMER, J. (1997). Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene number in Jurkat T cells. Int. J. Immunopharmac., 19, 709-720.
31. HAMILTON, R.A. & KREMER, J. (1995). The effects of food on methotrexate absorption. J. Rheumatol., 22, 630-632.
32. HAWKES, J., CLELAND, L. & JAMES, M. (1993). The effect of methotrexate in lipoxygenase metabolism in neutrophils from rats: in vitro and ex vivo studies. Agents Actions, 40, 181-185.
33. HAWKES, J., CLELAND, L., PROUDMAN, S. & JAMES, M. (1994). The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J. Rheumatol., 21, 55-58.
34. HU, S., MITCHKO, Y., ORONSKY, A. & KERWAR, S. (1998). Studies on the effect of methotrexate on macrophage function. J. Rheumatol., 15, 206-209.
35. JAFFE, E., NACHMAN, R., BECKER, C. & MINICK, C. (1973). Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest., 52, 2745-2756.
36. KALOGERIS, T.J., KEVIL, C.G., LAROUX, F.S., COE, L.L., PHIFER, T.J. & ALEXANDER, J.S. (1999). Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am. J. Physiol., 276, L9-L19.
37. KRANE, S., CONCA, W., STEPHENSON, M., AMENTO, E. & GOLDRING, M. (1990). Mechanisms of matrix degradation in rheumatoid arthritis. Ann. N.Y. Acad. Sci., 580, 340-354.
38. MANSAT-DE MAS, V., BEZOMBES, C., QUILLET-MARY, A., BETTAIEB, A., DE THONEL D'ORGEIX, A., LAURENT, G. & JAFFRÉZOU, J.-P. (1999). Implication of radical oxygen species in ceramide generation, c-Jun terminal kinase activation and apoptosis induced by daunorubicin. Mol. Pharm., 56, 867-874.
39. MERRIL, J., SHEN, C., SCHREIBMAN, D., COFFEY, D., ZAKJARENKO, O., FISHER, R., LAHITA, R., SALMON, J. & CRONSTEIN, B. (1997). Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum., 40, 1308-1315.
40. MORGAN, S., BAGGOTT, J., VAUGHN, W., AUSTIN, J., VEITCH, T., LEE, J., KOOPMAN, W., KRUMDIECK, C. & ALARCÓN, G. (1994). Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo controlled trial. Ann. Int. Med., 121, 833-841.
41. NEUMAN, M., CAMERON, R., HABER, J., KATZ, G., MALKIEWICZ, I. & SHEAR, N. (1999). Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatoxicity. Clin. Biochem., 32, 519-536.
42. NICOLLETTI, I., MIGLIORATI, G., PAGLIACCII, M., GRIGNANI, F. & RICCARDI, C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139, 271-279.
43. OGUEY, D., KOLLIKER, F., GERBER, N. & REICHEN, J. (1992). Effect of food on the bioavailability of low dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum., 35, 611-614.
44. PAILLOT, R., GENESTIER, L., FOURNEL, S., FERRARO, C., MIOSSEC, P. & REVILLARD, J. (1998). Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc., 30, 2348-2350.
45. PLOWS, D., PROBERT, L., GEORGOPOULOS, S., ALEXOPOULOU, L. & KOLLIAS, G. (1995). The role of tumour necrosis factor (TNF) in arthritis: studies in transgenic mice. Rheumatol. Eur., 24, 51-54.
46. RAHMAN, I. (2000). Regulation of nuclear factor-kappa B, activator protein-1, and glutathione levels by tumour necrosis factor-alpha and dexamethasone in aveolar epithelial cells. Biochem. Pharmacol., 60, 1041-1049.
47. RAU, R., SCHLEUSSER, B., HERBORN, G. & KARGER, T. (1997). Long term treatment of destructive rheumatoid arthritis with methotrexate. J. Rheumatol., 24, 1881-1889.
48. RICHARD-MICELI, C. & DOUGADOS, M. (2001). Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience. BiodDrugs, 15, 251-259.
49. ROBERTS, P., NEWBY, A., HALLET, M. & CAMPBELL, A. (1985). Inhibition of adenosine by reactive oxygen metabolite production by human polymorphonuclear leukocytes. Biochemical J., 227, 669-674.
50. RUSCHEN, S., STELLBERG, W. & WARNATZ, H. (1992). Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid patients are different from those from healthy controls. Clin. Exp. Immunol., 89, 32-37.
51. SCHWARTZ, P., BARNETT, S. & MILSTONE, L. (1995). Keratinocytes differentiate in response to inhibitors of deoxyribonucleotide synthesis. J. Dermatol. Sci., 9, 129-135.
52. SEITZ, M., ZWICKER, M. & LOETSCHER, P. (1998). Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum., 41, 2032-2038.
53. SMITH, P., KROHN, R., HERMANSON, G., MALLIA, A., GARTNER, F., PROVENZANO, M., FUJIMOTO, E., GOEKE, N., OLSON, B. & KLENK, D. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85.
54. SPERLING, R., BENINCASO, A., ANDERSON, COBLYN, J.K.F.A. & WEINBLATT, M. (1992). Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum., 35, 376-384.
55. SYNOLD, T., RELLING, M., BOYETT, J., RIVERA, G., SANDLUND, J., MAHMOUD, M., CRIST, W., PUI, C. & EVANS, W. (1994). Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest., 94, 1996-2001.
56. TAN, S., SAGARA, Y., LIN, Y., MAHER, P. & SCHUBERT, D. (1998). The regulation of reactive oxygen species production during programmed cell death. J. Cell Biol., 141, 1423-1432.
57. TIETZE, F. (1969). Enzymic methods for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem., 27, 502-522.
58. VAN DEN BERG, W. (1995). Uncoupling of inflammation and joint destruction in arthritis: pivotal role of interleukin 1 in destruction. Trends Cell Biol., 5, 392-399.
59. WEBER, C., ERL, W., WEBER, K. & WEBER, P. (1996). Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation, 93, 1488-1492.
60. WILLIAMS, A., JONES, S., GOODFELLOW, R., ARMOS, N. & WILLIAMS, B. (1999). Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulation in arthritis. B. J. Pharmacol., 128, 234-240.
61. YAMAUCHI, N., KURIYAMA, H., WATANABE, N., NEDA, H., MAEDA, M. & NIITSU, Y. (1989). Intracellular hydroxyl radical protection induced by recombinant human tumour necrosis factor and its implication in the killing of tumour cells in vitro. Cancer Res., 49, 1671-1675.
62. ZANGERLE, P., DE GROOTE, D., LOPEZ, M.R.J.M., VRINDTS, Y., FAUCHET, F., DEHART, I., JADOUL, M., RADOUX, D. & FRANCHIMONT, P. (1992). Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood II: application to rheumatoid arthritis and osteoarthritis. Cytokine, 4, 568-575.